Generic Name and Formulations:
Somatropin (rDNA origin) 5mg, 10mg; lyophilized pwd for SC inj after reconstitution; contains mannitol; diluents contain benzyl alcohol or metacresol.
Ferring Pharmaceuticals, Inc.
Indications for ZOMACTON:
Growth failure in children due to inadequate endogenous GH secretion. Replacement of endogenous GH in adults with GH deficiency.
Give by SC inj to the back of upper arm, abdomen, buttock, or thigh. Rotate inj sites. Non-weight based: initially ~0.2mg/day (range: 0.15–0.3mg/day); increase dose in increments of ~0.1–0.2mg/day every 1–2mos based on response and serum IGF-1 levels. Weight-based: initially 0.006mg/kg/day; increase dose based on individual requirements to max 0.0125mg/kg/day. Elderly: consider lower doses. Obese: weight-based dosing not recommended.
Individualize. Give by SC inj to the back of upper arm, abdomen, buttock, or thigh. Rotate inj sites. 0.18–0.3mg/kg weekly given either 3, 6, or 7 days per week (0.026–0.043mg/kg/day). Discontinue once epiphyseal fusion has occurred.
Acute critical illness due to open heart surgery, abdominal surgery, multiple accidental trauma or those with acute respiratory failure. Children with closed epiphysis. Active malignancy. Diabetic retinopathy. Prader-Willi syndrome (severely obese or w. respiratory impairment); see full labeling.
Increased mortality in those with acute critical illness (see Contraindications); weigh potential treatment benefit vs the potential risk. PWS: evaluate baseline respiratory function; monitor weight and for respiratory infection; interrupt if signs of upper airway obstruction and/or sleep apnea occurs. History of GHD secondary to intracranial neoplasm: monitor routinely for tumor progression or recurrence. Increased risk of developing malignancies. Monitor for increased growth or malignant changes of preexisting nevi. Diabetes. Obesity. Hypothyroidism. Scoliosis. Turner syndrome. Monitor bone age, thyroid function, glucose tolerance, and for intracranial hypertension (do baseline and periodic funduscopic exams). Hypoadrenalism: monitor for reduced serum cortisol levels. May elevate serum phosphorus, alkaline phosphatase, parathyroid hormone, IGF-1. Elderly. Neonates: reconstitute with normal saline for inj instead. Pregnancy, nursing mothers: reconstitute with normal saline or use benzyl alcohol-free formulation.
May require increase in maintenance or stress doses of glucocorticoids in hypoadrenalism. May be antagonized by glucocorticoids, oral estrogens; adjust doses. May affect CYP450 substrates; monitor. Antihyperglycemic agents may need to be adjusted. Concomitant thyroid replacement therapy; adjust if needed.
Growth hormone (GH).
Upper RTI, fever, pharyngitis, headache, otitis media, edema, arthralgia, paresthesia, myalgia, pain, rhinitis, peripheral edema, back pain, flu syndrome, AST increased; fluid retention, severe hypersensitivity reactions, pancreatitis (monitor); also in children: slipped capital femoral epiphysis.
Vials—1 (w. diluent)
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|